This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Charles River Associates (CRA) Strengthens Capabilities In Life Sciences

Stocks in this article: CRAI

Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing management, economic, and financial consulting services, today announced that Jeffrey Aroy has joined the firm as a vice president in the Life Sciences Practice based in Boston. Mr. Aroy has more than 20 years of experience as a consultant and executive in the life sciences industry.

“Jeffrey Aroy’s knowledge of the clinical and commercial pillars of the life sciences industry is an excellent complement to CRA’s life sciences offering and we are pleased to welcome him to CRA,” said CRA's President and Chief Executive Officer Paul Maleh. “Jeff has direct industry experience, as a founder and leader of multi-million dollar life sciences companies, as well as an extensive consulting background where he has advised on corporate strategy issues and strategic marketing concerns throughout the product life cycle. His comprehensive knowledge of the industry dovetails with the expertise clients seek from CRA.”

Mr. Aroy’s consulting practice focuses on growth strategies in life sciences, with emphases on product launch, portfolio prioritization, companion diagnostic, and emerging markets strategies. He has deep expertise in multiple therapeutic areas and has worked across industry sectors covering large pharma, biotech, medical devices, and diagnostics. Mr. Aroy joins CRA from Leerink Swann where he was a Senior Managing Director and business unit head of Leerink’s professional consulting practice. Mr. Aroy’s responsibilities included developing and leading some of Leerink’s significant relationships with large life sciences companies.

In addition, Mr. Aroy has executive experience as a leader of two growth-stage diagnostics companies, both of which were acquired for a combined half billion dollars. As General Manager at Berkeley HeartLab, he managed a $60 million business focused on advanced cardiovascular products and was responsible for sales, marketing, and establishing a network of clinics, among other areas. As Chief Operating Officer of Cholestech, a point-of-care cardiovascular testing company, Mr. Aroy drove growth by forming novel partnerships with pharmaceutical companies to help increase diagnosis and treatment of heart disease.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs